Sientra, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
November 09, 2023 at 04:14 pm EST
Share
Sientra, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was USD 19.54 million compared to USD 22.57 million a year ago. Net loss was USD 14.77 million compared to USD 14.98 million a year ago. Basic loss per share from continuing operations was USD 1.31 compared to USD 2.37 a year ago. Basic loss per share was USD 1.31 compared to USD 2.38 a year ago.
For the nine months, sales was USD 65.23 million compared to USD 65.48 million a year ago. Net loss was USD 37.14 million compared to USD 51.33 million a year ago. Basic loss per share from continuing operations was USD 3.23 compared to USD 8.16 a year ago. Basic loss per share was USD 3.23 compared to USD 8.19 a year ago.
Sientra, Inc. is a medical aesthetics company. The Company is engaged in transformative treatments and technologies focused on advancing plastic surgery. The Company provides medical aesthetics products to certified plastic surgeons and patients. It has developed a portfolio of products with technologically differentiated characteristics, supported by independent laboratory testing and strong clinical trial outcomes. The Company sells its breast implants, breast tissue expanders, and fat transfer system for reconstruction procedures predominantly to hospitals and surgery centers, and its BIOCORNEUM scar management products to plastic surgeons, dermatologists and other specialties. The Company's brands also include Sientra, Sientra Platinum20, Sientra Full Circle, Sientra Smooth, Sientra Teardrop, AlloX, AlloX2, Anatomical Controlled, BIOCORNEUM, Curve, Dermaspan, Luxe, Softspan, Silishield, AuraClens and Viality.
SIENTRA, INC. 
